An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

Completed · Phase 2 · Has a placebo group

Conditions studied: Migraine Headaches

In brief

A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.

Key facts

Study ID

NCT02856802

Run by

Upsher-Smith Laboratories

People needed

107

Starts

2016-07-11

Expected to finish

2017-02-10

Last updated by the study team

2021-03-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A history of episodic migraine who experience an average of 2 to 8 migraine attacks per month for at least the past 12 months, with no more than 14 headache days per month, and with 48 hours of headache free time between migraine headaches
• Patients who have migraine with or without aura. If migraine with aura, the aura cannot last longer than 60 minutes.
• Patients who are willing and able to:
• Evaluate and record pain, migraine symptoms, and study medication effectiveness information in real-time using a diary for the duration of the study;
• Record each instance of the use of study medication and rescue medication in a patient diary in real-time for the duration of the study;
• Comply with all other study procedures and scheduling requirements.

You may not qualify if…

• Minors, even if they are in the specified study age range
• Medication overuse:
• Opioids ≥ 10 days during the 90 days prior to screening
• Combination medications (e.g., Fiorinal®) ≥ 10 days during the 90 days prior to screening (only applies if combination medication contains an opioid and/or barbiturate)
• Nonsteroidal Anti-inflammatory Drugs or other simple medications ˃ 14 days a month during the 90 days prior to screening
• Triptans or ergots ≥ 10 days a month during the 90 days prior to screening
• Treated with onabotulinumtoxinA (Botox®) or other botulinum toxin treatment within 4 months prior to screening for migraine prophylaxis (patients who were treated with same for cosmetic purposes may be allowed on a case-by-case basis after approval from the Medical Monitor)
• A history of or current neurological or psychiatric impairment, or cognitive dysfunction that, in the opinion of the Investigator, would compromise data collection
• Use of antipsychotics at least 15 days prior to randomization
• Patients who received treatment with an investigational drug or device within 30 days prior to randomization, or within 3 months if associated with central nervous system
• Patients who participated in a central nervous system clinical trial within 3 months prior to randomization
• Patients who test positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody serology testing
• Patients who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the clinical study research site

Where it is running

• Site 30 — San Diego, California, United States
• Site 11 — Santa Monica, California, United States
• Site 31 — Boston, Massachusetts, United States
• Site 18 — Ann Arbor, Michigan, United States
• Site 02 — Albuquerque, New Mexico, United States
• Site 29 — Rochester, New York, United States
• Site 25 — Williamsville, New York, United States
• Site 33 — Mt. Pleasant, South Carolina, United States
• Site 28 — West Jordan, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.